Eldorado Gold heads into the back half of September with its sharpest weekly loss in months — down 7.5% to C$55.95 — while short sellers quietly rebuild positions and the lending market remains broadly relaxed.
The week's move was sector-wide rather than stock-specific. Closest peers IMG fell 1.7%, ARIS dropped 6.4%, and K shed 6.2% over the same period. ELD's decline tracks the group but sits toward the deeper end of the range. That context matters: this looks like a gold complex pullback, not a company-specific derating.
Short sellers have nudged positions higher over the week, but the borrow market tells a story of limited conviction. Short interest climbed 7.4% over five sessions to 1.7% of free float — still low in absolute terms. Availability remains extraordinarily loose at 921%, meaning roughly nine shares are available to borrow for every one already short. That reading has dropped roughly 17% on the week from above 1,300%, but it is still comfortably above the 12-month floor of 505%. Cost to borrow, at 0.57%, is cheap by any standard. The short score of 31.6 has drifted higher this week from 30.2 on Thursday, but remains well within the lower half of the universe. Nothing in the lending market points to organised bearish conviction — positioning looks cautious rather than crowded.
The ownership picture adds an interesting wrinkle. Several large passive and active managers have been building stakes in size. Capital Research Global Investors filed a 13G/A in August lifting its disclosed position from 5.2% to 6.9% of shares. Van Eck Associates — a natural gold-sector holder — holds 7.2% and filed an update in mid-August. L1 Capital filed a fresh 13G in May disclosing a 5.3% stake. Hamblin Watsa Investment Counsel and Helikon Investments each added the full extent of their reported positions as new entrants in the data. None of these are activist 13D filings; all carry the standard caveat that stakes are as-last-disclosed and holders dropping below 5% may not file again. But the directional flow from multiple institutional buyers in recent quarters stands in contrast to the minor insider selling — a small discretionary sale by one executive in late August and routine option exercises — which at a significance score of 3 out of 10 reads as routine compensation activity rather than a directional signal.
Valuation multiples have compressed with the price. The EV/EBITDA multiple has contracted by 0.63 turns over the past 30 days to 4.6x. The PE now runs at 8.4x, down 0.75 turns on the week. For a producer with 40%-plus year-on-year sales growth in its most recent ORTEX score reading, those are undemanding levels — though the quality pillar carries a caveat, with free cash flow running modestly negative through mid-year. The 30-day EPS momentum factor rank at 79 is one of the stronger readings across the factor scorecard, suggesting forward estimates have been moving up even as the stock has pulled back.
Earnings are next scheduled for October 29. The most recent post-result pattern warrants attention: in the two quarters ending July, the stock fell 2.5% and 5.8% on the day of results respectively, then recovered to gains of 15% and 12% over the following five sessions. That recovery dynamic is the pattern to watch heading into Q3 results — whether the initial reaction and subsequent drift hold given a stock entering the print already down roughly 7% on the week.
See the live data behind this article on ORTEX.
Open ELD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
